RxDoctor Payments Data
★ My doctorsLook up a doctor →

Raquel Vaughan, NP

Acute Care · Oxford, MSNPI 1407958382

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 9.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,743, 2.4 times the $740 reported in 2021. Among acute care clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,194in general payments, 2019–2025

Across 298 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$604
  • Pfizer$545
  • AstraZeneca$534
  • Philips North America LLC$531
  • Novartis$463
  • Boehringer Ingelheim$425
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$6,181100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)28$604
Pfizer34$545
AstraZeneca27$534
Philips North America LLC28$531
Novartis25$463
Boehringer Ingelheim21$425
Merck24$415
E.r. Squibb & Sons, L.L.C.17$340
Amgen20$300
Boston Scientific8$278
Medtronic4$252
Novo Nordisk9$211
Bayer6$205
Sanofi-aventis U.S. LLC9$194
Alnylam Pharmaceuticals Inc.4$150
Abbott2$145
Irhythm Technologies, Inc.5$98
Esperion Therapeutics, Inc.5$81
Impulse Dynamics (USA) Inc.3$66
Regeneron Healthcare Solutions, Inc.2$48
Ionis Pharmaceuticals, Inc.2$47
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)3$45
Scpharmaceuticals Inc.2$33
Bridgebio Pharma, Inc.1$30
Cvrx, Inc.2$30
Terumo Medical Corporation1$29
Atricure, Inc.2$28
Amarin Pharma, Inc.1$21
Chiesi USA, Inc.1$18
Lexicon Pharmaceuticals, Inc.1$14
Heartflow, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,194 in reported general payments places this provider in the 90th percentile of 223 acute care providers in Mississippi.

See all acute care providers in Mississippi →

Medicare billing

Part B allowed, 2024
$1,663
Medicare patients
16
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Amlodipine Besylate13$56
Atorvastatin Calcium11$6

Paid to pharmacies, not to this prescriber.

Other acute care in Oxford

See the full list for Mississippi →

Where these figures come from

Is this you, or does something look wrong? →